How Is Ketamine Tablet Different From IV Infusion?

This is one of the most common questions among patients exploring ketamine therapy. The short answer: ketamine tablet and IV ketamine are the same drug administered in fundamentally different ways, producing different pharmacological experiences, different clinical applications, and different practical considerations. Here's a complete breakdown.

The Basics: Same Drug, Different Journey

Both oral and IV ketamine use racemic ketamine hydrochloride — the same active molecule. The difference is how it gets into your body and what happens to it along the way.

IV ketamine: Injected directly into a vein, 100% of the drug immediately enters systemic circulation. No digestion, no liver metabolism on the first pass. Peak plasma levels are reached rapidly and are substantially higher than any oral dose would produce.

Ketamine tablet: Swallowed, the drug travels to the stomach and small intestine, is absorbed, and then passes through the liver before reaching systemic circulation. Approximately 75–90% is converted to metabolites (primarily norketamine) during this first pass. Only 10–25% of the oral dose reaches circulation as unchanged ketamine. For a deeper dive, see bioavailability explained.

How They Differ: A Point-by-Point Comparison

Bioavailability

Onset of Effects

IV: Effects begin within minutes of starting the infusion. Patients at a standard clinical dose of 0.5 mg/kg over 40 minutes typically experience significant dissociation by 10–15 minutes into the infusion.

Oral: Effects begin 30–60 minutes after swallowing (faster with troches held in the mouth — 15–30 minutes). There is a gradual onset rather than the rapid rise of IV.

Why it matters: For patients in acute psychiatric crisis or who need rapid relief, IV produces effects measurably faster. For routine therapy, the oral onset is clinically acceptable.

Peak Effect

IV: Peak plasma levels occur during or immediately after the infusion. The experience is often described as intense and immersive — significant dissociation is essentially universal at the 0.5 mg/kg clinical dose.

Oral: Peak plasma levels occur 1–2 hours after ingestion. At typical therapeutic doses, the experience is gentler than IV — mild to moderate dissociation rather than profound alteration. Higher oral doses can produce more intense effects, but the slower absorption makes the experience less dramatic than IV even at equivalent bioavailability.

Duration

IV: The infusion itself is 40 minutes to 1 hour (for psychiatric indications). After the infusion stops, plasma levels fall rapidly. Most patients are substantially back to baseline 1–2 hours post-infusion.

Oral: Effects last 3–5 hours due to slower absorption, continued GI uptake, and norketamine's longer half-life. The longer duration means more recovery time is needed but also means a single oral dose provides extended therapeutic exposure.

The Experience

IV: More intense, more immersive, more profoundly dissociative. Some patients describe it as dream-like or deeply introspective. The experience ends relatively quickly. Some find it powerful and transformative; others find the intensity uncomfortable.

Oral: Gentler, more gradual, longer-lasting. Mild mental softening at therapeutic doses. Many patients can hold a conversation, although judgment and driving are impaired. The oral experience is often described as more manageable and less frightening for anxious patients.

Antidepressant Effect

Both routes produce antidepressant effects through ketamine's glutamatergic mechanisms. Research suggests:

• IV: Larger and more reliable effect per session; effects typically emerge within hours
• Oral: Somewhat lower effect per session; effects emerge within 24–72 hours; may be sustained more easily through ongoing maintenance

For acute severe depression, IV has a stronger evidence base. For maintenance therapy, oral is more practical and the available evidence suggests comparable outcomes with appropriate dosing.

Cost

IV: $400–$800 per infusion at most US clinics; no insurance coverage for psychiatric indications in most cases. A standard 6-infusion induction course costs $2,400–$4,800.

Oral: $8–$30 per dose (compounded tablets or troches). Monthly costs of $200–$600 for typical protocols. Accessible via telehealth for $130–$400/month bundled.

Access

IV: Requires an infusion clinic, which may not be in every geographic area. Requires travel, time, and clinic scheduling.

Oral: Can be prescribed via telehealth and shipped to home. Can be taken at home in most protocols. Much more accessible, particularly in rural areas.

Clinical Monitoring

IV: Administered in clinic with nursing supervision; blood pressure, heart rate, and clinical status monitored throughout.

Oral: Often taken at home. Monitoring is self-reported between prescriber visits. Requires appropriate patient selection for home-based use.

Driving Restrictions

Both routes: Do not drive until effects have fully resolved. For IV, this typically means the rest of the day (most clinics require someone to drive the patient home). For oral, this means at least 8 hours after dosing, often the next day for therapeutic doses.

Which Is Better?

"Better" depends entirely on the clinical situation:

IV ketamine is better when:

• Acute, severe depressive episode requiring rapid response
• High suicide risk requiring rapid anti-suicidal effect
• Strong acute antidepressant induction is the goal
• Access to an IV clinic is feasible

Ketamine tablet is better when:

• Maintenance therapy after IV induction
• Geographic or financial barriers to IV access
• Daily or near-daily dosing is preferred (impractical with IV)
• The patient cannot tolerate the intensity of IV experiences
• Home-based treatment is clinically appropriate
• Chronic pain requiring continuous dosing

The most common clinical approach: IV ketamine for acute induction (the first 2–4 weeks), followed by ketamine tablet for maintenance. This combines the reliability of IV's acute effect with the practicality of oral maintenance.

Questions to Ask Your Prescriber

1. Am I a candidate for IV, oral, or both?
2. If I start with IV, is there a plan for transitioning to oral maintenance?
3. If I start with oral, what would prompt you to recommend IV?
4. How will you monitor my response regardless of which route I use?

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• Healthcare.gov: Understanding Costs — Federal marketplace resource explaining insurance terminology and out-of-pocket healthcare costs